This article highlights the potential benefits of sodium-glucose cotransporter-2 (SGLT2) inhibition as a therapeutic strategy for acute myocardial infarction, suggesting its promising role in improving outcomes for patients. Here, SLC5A2 is linked to myocardial infarction.